{"id":"W2150475127","doi":"10.1093/annonc/mdh278","title":"A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131","year":2004,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Regional Cancer Foundation; BC Cancer Agency","funders":"AstraZeneca Canada","keywords":"Docetaxel; Medicine; Taxane; Neutropenia; Regimen; Internal medicine; Carboplatin; Cancer; Clinical trial; Prostate cancer; Phases of clinical research; Chemotherapy; Oncology; Surgery; Cisplatin; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001392029,0.002136745,0.002981401,0.0005849617,0.0007596971,0.001150798,0.001283957,0.001772406,0.006318507],"category_scores_gemma":[0.001399863,0.0008494703,0.00231794,0.0007458068,0.001494257,0.0008645856,0.0003668257,0.004657709,0.001222308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001844729,"about_ca_system_score_gemma":0.003796228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008431534,"about_ca_topic_score_gemma":0.0278571,"domain_scores_codex":[0.9995389,0.0002085338,0.00001596441,0.00007792288,0.00003977585,0.000118896],"domain_scores_gemma":[0.9990663,0.0001706506,0.0001379777,0.00006149218,0.00004523425,0.0005183045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8996552,0.02918099,0.001972012,0.0007608637,0.001176951,0.0001508965,0.0001918065,0.001824266,0.007221365,0.0003383382,0.007509186,0.0500182],"study_design_scores_gemma":[0.8872765,0.1065471,0.003383163,0.00002275825,0.0002866751,0.00008275468,0.00003564003,0.0004432457,0.0003679139,0.000121033,0.00141136,0.00002199189],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797376,0.005410296,0.0005063647,0.001802222,0.0004788003,0.003851637,0.003245187,0.0001767014,0.004791274],"genre_scores_gemma":[0.9731966,0.005917558,0.002094777,0.001919255,0.00045484,0.003675421,0.00358372,0.00006384424,0.009093912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008431534,"threshold_uncertainty_score":0.02113754,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1989070396041286,"score_gpt":0.5251946068362316,"score_spread":0.3262875672321031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}